a virtual currency Top Knowledge

Li Dongsheng said that low-price competition has no way out, and it will only get involved. On December 11th, at TCL Global Innovation Conference, founder Li Dongsheng said that in the current market competition, low-price competition has no way out, and it will only get involved in endless "involution". To surpass its competitors, it is necessary to strive for more breakthroughs in high-end products. He Jun, vice president of TCL Industry, talked about the current development of industrial software enterprises in China in a subsequent interview. He also said that from the aspects of financing environment and market support for enterprises, China is not an environment where good software enterprises can be born at present, but in the long run, industrial software may make a breakthrough in China software, and this time will not be very fast, and it will not be seen for three or five years.SHIBOR reported 1.4040% overnight, down by 7.80 basis points. In 7 days, SHIBOR reported 1.7580%, up 12.30 basis points. SHIBOR reported 1.7350% in three months, down by 0.50 basis point.The General Administration of Market Supervision launched a pilot program to deepen credit repair. The gold T+D of Shanghai Gold Exchange fell by 1.01% to 617.82 yuan/gram at the beginning of trading on Friday, December 13th. Silver T+D of Shanghai Gold Exchange fell 1.27% to 7722.0 yuan/kg at the beginning of trading on Friday, December 13th.

The concept of robot bottomed out and Tianqi shares rose linearly, and Tianqi shares rose linearly. Before that, the construction industry went out of 9 boards in 10 days, Astar went out of 13 boards in 21 days, and Tongda Power went up. Hanyu Group, Maihe, Jiangsu Reilly, Hanwei Technology and Best were among the top gainers.The merger of Guotai Junan Haitong Securities was approved by the shareholders' meeting, and the merger and reorganization of Guotai Junan and Haitong Securities completed a key step. On the evening of December 13, the two companies simultaneously announced the resolutions of the shareholders' meeting. The merger and reorganization transaction plan and other related proposals were reviewed by the shareholders' meeting and passed by high votes. The merger and reorganization of Guotai Junan and Haitong Securities is the first merger and reorganization of head brokers since the implementation of the new "National Nine Articles". It is also the largest A+H bilateral market merger and the largest integration case of listed brokers in the history of China capital market, and the largest M&A project in international investment banking since 2008, involving multi-business licenses and a number of domestic and foreign listed subsidiaries.On the 13th, the No.20 rubber fell by 2.05%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract No.20 rubber 2502 was closed, with a turnover of 159,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 5,142 lots. A total of 205,200 lots were traded in the No.20 rubber futures contract, an increase of 8,176 lots over the previous day. The first 20 seats in the contract held 84,200 lots, an increase of 812 lots over the previous day. Short positions in the top 20 seats of the contract were 94,500 lots, a decrease of 1,708 lots from the previous day. (Sina Futures)

Zhendong Pharmaceutical has set up a new health management service company. The enterprise search APP shows that recently, Shanxi Zhendong Health Management Service Co., Ltd. was established, with Zhao Jin as the legal representative and a registered capital of 10 million yuan. Its business scope includes: remote health management services; Health consulting services (excluding medical services), etc. Enterprise investigation shows that the company is wholly owned by Zhendong Pharmaceutical.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.Centeno, Governing Committee of the European Central Bank: Fortunately, yesterday's decision of the European Central Bank was unanimously adopted.